Seres Therapeutics, Inc. (NASDAQ:MCRB) Short Interest Down 95.2% in April

Seres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report) was the recipient of a significant decrease in short interest during the month of April. As of April 15th, there was short interest totalling 763,100 shares, a decrease of 95.2% from the March 31st total of 16,010,000 shares. Currently, 12.0% of the shares of the stock are short sold. Based on an average daily volume of 70,300 shares, the short-interest ratio is currently 10.9 days.

Seres Therapeutics Stock Up 3.2 %

Seres Therapeutics stock traded up $0.30 during trading hours on Wednesday, hitting $9.70. The stock had a trading volume of 130,941 shares, compared to its average volume of 157,643. The business's 50 day simple moving average is $12.58 and its 200-day simple moving average is $15.05. Seres Therapeutics has a one year low of $7.18 and a one year high of $30.60. The stock has a market cap of $84.56 million, a price-to-earnings ratio of -42.17 and a beta of 2.54.

Hedge Funds Weigh In On Seres Therapeutics

A number of hedge funds have recently made changes to their positions in MCRB. Avantax Advisory Services Inc. grew its position in Seres Therapeutics by 170.9% in the 4th quarter. Avantax Advisory Services Inc. now owns 45,179 shares of the biotechnology company's stock valued at $38,000 after purchasing an additional 28,500 shares during the period. Jane Street Group LLC grew its holdings in shares of Seres Therapeutics by 181.4% during the fourth quarter. Jane Street Group LLC now owns 58,736 shares of the biotechnology company's stock valued at $49,000 after buying an additional 37,866 shares during the last quarter. Virtu Financial LLC raised its holdings in shares of Seres Therapeutics by 44.8% in the 3rd quarter. Virtu Financial LLC now owns 58,791 shares of the biotechnology company's stock worth $56,000 after acquiring an additional 18,191 shares during the last quarter. Northern Trust Corp raised its stake in shares of Seres Therapeutics by 20.4% in the fourth quarter. Northern Trust Corp now owns 262,683 shares of the biotechnology company's stock worth $218,000 after purchasing an additional 44,461 shares during the last quarter. Finally, State Street Corp raised its stake in shares of Seres Therapeutics by 12.9% during the 3rd quarter. State Street Corp now owns 383,248 shares of the biotechnology company's stock worth $363,000 after purchasing an additional 43,700 shares during the period. 59.34% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently commented on MCRB. Chardan Capital reissued a "buy" rating and set a $25.00 price target on shares of Seres Therapeutics in a report on Thursday, March 20th. StockNews.com raised Seres Therapeutics from a "sell" rating to a "hold" rating in a research note on Wednesday, April 23rd. Finally, The Goldman Sachs Group dropped their target price on shares of Seres Therapeutics from $20.00 to $15.00 and set a "sell" rating for the company in a report on Friday, March 14th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $80.00.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.